Sugi Predict

Sugi Predict / Compounds / SCHEMBL379862

SCHEMBL379862

SCHEMBL379862

COc1ccc(C(F)(F)F)cc1NC(=O)Nc1ccccc1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 4/20 0.59
▸ NPC1 O15118 3/20 0.59
▸ SMN1; SMN2 Q16637 3/20 0.59
▸ KMT2A Q03164 4/20 0.59
▸ MEN1 O00255 3/20 0.59
▸ HTT P42858 2/20 0.59
▸ MAPT P10636 2/20 0.59
▸ KDM4E B2RXH2 3/20 0.58
▸ MAPK14 Q16539 1/20 0.57
▸ HPGD P15428 1/20 0.56
▸ RAF1 P04049 1/20 0.53
▸ PKM P14618 1/20 0.53
▸ NFKB1 P19838 1/20 0.53
▸ NFKB2 Q00653 1/20 0.53
▸ RELA Q04206 1/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ GAA P10253 2/20 0.52
▸ LMNA P02545 1/20 0.52
▸ P2RY1 P47900 1/20 0.52
▸ RXFP1 Q9HBX9 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30667490 1.00 RAB9A (0.59) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL31440788 0.89 KMT2A (0.61) KMT2AMEN1HTTMAPTKDM4E
SCHEMBL1463353 0.87 MAPK14 (0.57) KMT2AMEN1HTTMAPTKDM4E
SCHEMBL4244357 0.86 NPC1 (0.56) RAB9ANPC1SMN1; SMN2KMT2AMEN1
SCHEMBL4238303 0.85 MAPT (0.53) RAB9ASMN1; SMN2KMT2AMEN1HTT
SCHEMBL15229698 0.84 MEN1 (0.54) RAB9ASMN1; SMN2KMT2AMEN1HTT
SCHEMBL30863324 0.83 RAF1 (0.51) KMT2AMEN1HTTMAPTKDM4E
SCHEMBL8793986 0.83 RAF1 (0.51) KMT2AMEN1HTTMAPTKDM4E
SCHEMBL31686438 0.83 RAF1 (0.51) KMT2AMEN1HTTMAPTKDM4E
SCHEMBL30863330 0.83 RAF1 (0.51) KMT2AMEN1HTTMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1893587-B1 METHOD FOR PRODUCING DIHYDROQUINAZOLINES AICURIS GMBH & CO KG (DE) 2012-01-25 — — EP claimed
US-8084604-B2 Process for the preparation of dihydroquinazolines Aicuris GmbH & Co., KG (DE) 2011-12-27 — — US claimed
US-20090221822-A1 Process for the Preparation of Dihydroquinazolines BAYER HEALTHCARE AG (DE) 2009-09-03 — — US claimed
US-RE49897-E1 Salts of a dihydroquinazoline derivative AIC246 AG & CO. KG (DE) 2024-04-02 — — US disclosed
EP-4328218-A2 PHARMACEUTICAL PREPARATION COMPRISING AN ANTIVIRAL DIHYDROQUINAZOLINE DERIVATIVE AIC246 AG & Co. KG (DE) 2024-02-28 — — EP disclosed
US-10603384-B2 Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative AICURIS GMBH & CO. KG (DE) 2020-03-31 — — US disclosed
US-10287254-B2 Salts of a dihydroquinazoline derivative AICURIS GMBH & CO. KG (DE) 2019-05-14 — — US disclosed
US-10287254-B2 Salts of a dihydroquinazoline derivative AICURIS GMBH & CO. KG (DE) 2019-05-14 — — US disclosed
US-20170362186-A1 Salts of a dihydroquinazoline derivative AICURIS GMBH & CO. KG (DE) 2017-12-21 — — US disclosed
US-20170362186-A1 Salts of a dihydroquinazoline derivative AICURIS GMBH & CO. KG (DE) 2017-12-21 — — US disclosed
US-20170362186-A1 Salts of a dihydroquinazoline derivative AICURIS GMBH & CO. KG (DE) 2017-12-21 — — US disclosed
US-20120130072-A1 PROCESS FOR THE PREPARATION OF DIHYDROQUINAZOLINES AICURIS GMBH & CO. KG (DE) 2012-05-24 — — US disclosed
US-20120130072-A1 PROCESS FOR THE PREPARATION OF DIHYDROQUINAZOLINES AICURIS GMBH & CO. KG (DE) 2012-05-24 — — US disclosed
EP-1893587-B1 METHOD FOR PRODUCING DIHYDROQUINAZOLINES AICURIS GMBH & CO KG (DE) 2012-01-25 — — EP disclosed
US-8084604-B2 Process for the preparation of dihydroquinazolines Aicuris GmbH & Co., KG (DE) 2011-12-27 — — US disclosed
US-8084604-B2 Process for the preparation of dihydroquinazolines Aicuris GmbH & Co., KG (DE) 2011-12-27 — — US disclosed
US-8084604-B2 Process for the preparation of dihydroquinazolines Aicuris GmbH & Co., KG (DE) 2011-12-27 — — US disclosed
US-20090221822-A1 Process for the Preparation of Dihydroquinazolines BAYER HEALTHCARE AG (DE) 2009-09-03 — — US disclosed
US-20090221822-A1 Process for the Preparation of Dihydroquinazolines BAYER HEALTHCARE AG (DE) 2009-09-03 — — US disclosed
US-20090221822-A1 Process for the Preparation of Dihydroquinazolines BAYER HEALTHCARE AG (DE) 2009-09-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10287254-B2 Salts of a dihydroquinazoline derivative BAD, IRF3, VHL RAB9A 509/4885NPC1 987/4885SMN1; SMN2 1957/4885
US-20170362186-A1 Salts of a dihydroquinazoline derivative BAD, CHUK, EIF2AK2 RAB9A 748/4885NPC1 1872/4885SMN1; SMN2 2811/4885
US-20120130072-A1 PROCESS FOR THE PREPARATION OF DIHYDROQUINAZOLINES QDPR, DHPS, DHX15 RAB9A 1931/4885NPC1 1171/4885SMN1; SMN2 4574/4885
US-10603384-B2 Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative RPL5, EIF2AK2, RPL35 RAB9A 1512/4885NPC1 743/4885SMN1; SMN2 2068/4885
US-20090221822-A1 Process for the Preparation of Dihydroquinazolines QDPR, DHPS, DHX15 RAB9A 1931/4885NPC1 1171/4885SMN1; SMN2 4574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.